Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07529717 · ClinicalTrials.gov registry record · Phase 1
First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer
A Phase 1 study, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT07529717 is a Phase 1 study that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 42 participants.
The verdict
NCT07529717, a Phase 1 study, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This study is being conducted to learn more about the safety, tolerability, and effectiveness of an experimental treatment for metastatic prostate cancer called AZD8359. The study is split into different modules which will look at AZD8359 delivered by different methods. The study is also further split into 2 parts, Part A which will test different dose levels and dosing schedules of AZD8359 to determine which doses are the best in terms of safety and side effects (dose escalation), and Part B will further test at least two AZD8359 doses in a larger group of participants (dose expansion).
Interventions
- DRUG AZD8359
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2026-05-18 |
| Est. Completion | 2027-11-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07529717
The ClinicalTrials.gov registry entry for NCT07529717 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AZD8359 is the first listed.
NCT07529717 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07529717 about?
NCT07529717 is a clinical study titled "First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer". This study is being conducted to learn more about the safety, tolerability, and effectiveness of an experimental treatment for metastatic prostate cancer called AZD8359. The study is split into different modules which will look at AZD8359 delivered by different methods. The study is also further spl...
What is the current status of trial NCT07529717?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2026-05-18. Estimated completion is 2027-11-17.
What interventions are being tested in trial NCT07529717?
The interventions under investigation include: AZD8359 (DRUG).
Who is sponsoring clinical trial NCT07529717?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.